Using Synthetic Data for Clinical Trial Simulation and Feasibility Studies

Synthetic data is transforming clinical trial simulation and feasibility studies by allowing researchers to test trial designs before enrolling real patients. By creating privacy-safe, realistic patient datasets, teams can simulate enrollment, refine eligibility criteria, predict risks, and validate assumptions early.

This proactive approach reduces delays, lowers costs, and increases the chances of trial success.

Clinical trials are the backbone of medical innovation, but they are also among the most expensive, time-consuming, and unpredictable stages of drug development. Delays in patient recruitment, poorly designed eligibility criteria, and late-stage protocol amendments can push timelines back by months or even years, driving costs and putting promising therapies at risk.

What makes this challenge even more complex is that many of these issues only surface after a trial has already begun. By the time sponsors realize that recruitment targets are unrealistic or that a protocol doesn’t reflect real-world patient populations, the damage is often done.

This is where synthetic data is changing the conversation.

By creating realistic, privacy-safe patient datasets, synthetic data for healthcare allows researchers to simulate clinical trials and assess feasibility before enrolling a single participant. Trial designs can be tested, refined, and optimized in a virtual environment, helping teams anticipate risks, validate assumptions, and make smarter decisions earlier in the process.

As clinical research moves toward faster, more patient-centric, and data-driven models, synthetic data is emerging as a powerful tool to design better trials from the very beginning, by strengthening the foundation on which successful trials are built.

What is Synthetic Data in Clinical Research?

Synthetic data refers to artificially generated data that statistically mirrors real-world clinical data without containing any identifiable patient information.

Generated using advanced techniques such as machine learning, generative AI, and statistical modeling, synthetic datasets preserve the patterns, distributions, and relationships found in real patient data, while remaining privacy-safe.

In clinical research, synthetic data can replicate:

• Patient demographics and disease characteristics
• Treatment responses and outcomes
• Longitudinal health records and event timelines

Unlike real-world data (RWD), synthetic data is not constrained by privacy regulations or access limitations. And unlike basic simulated data, it is grounded in real clinical patterns, making it far more realistic and useful for decision-making.

Role of Synthetic Data in Clinical Trial Simulation

Clinical trial simulations are an essential part of modern drug development, allowing researchers to predict trial outcomes, optimize study designs, and reduce the risk of costly failures.

Synthetic data for healthcare plays a transformative role in this process by providing realistic, privacy-compliant datasets that replicate patient populations and disease patterns without exposing actual patient information.

Mimicking Patient Populations

Synthetic data can simulate diverse patient demographics, genetic profiles, comorbidities, and treatment responses.

This allows researchers to test trial protocols on virtual populations that mirror real-world variability, ensuring the study design is robust before actual patient enrollment begins.

Testing Trial Protocols

Researchers can use synthetic datasets to evaluate various trial scenarios, such as dosing regimens, treatment schedules, or inclusion/exclusion criteria. This helps identify potential risks, inefficiencies, or bottlenecks early, reducing protocol amendments later in the trial.

Predicting Outcomes and Adverse Events

By running simulations on synthetic datasets, trial teams can forecast possible outcomes, response rates, or adverse events under different scenarios. This predictive capability supports data-driven decision-making, improving the chances of trial success.

Accelerating Study Timelines

Generating and using synthetic data is faster than waiting for real-world patient data. It enables iterative simulations and rapid adjustments to trial designs, significantly shortening the planning phase and helping sponsors move faster toward clinical execution.

Enabling “What-If” Scenarios

Synthetic data allows researchers to explore multiple hypothetical scenarios without risk to actual patients. These simulations often resemble digital twins, where virtual patient cohorts are stress-tested against changes such as higher dropout rates, older populations, or increased comorbidities.

Compliance and Privacy

Since synthetic data doesn’t correspond to real patients, it avoids privacy concerns and regulatory hurdles while still maintaining statistical fidelity. This is particularly valuable when testing trials across multiple geographies with strict data protection laws.

Synthetic data lets researchers safely test trials, reduce risk, and bring therapies to patients faster.

How does Synthetic Data transforms Trial Feasibility Analysis?

From Assumptions to Predictive Insights

Traditional feasibility relies heavily on historical data and assumptions. Synthetic data enables predictive modeling by simulating realistic patient populations.

Creating high-fidelity synthetic patient records helps teams assess feasibility with greater confidence before trials begin.

Smarter Patient Recruitment Forecasting

Synthetic data allows researchers to simulate enrollment across sites and regions. This helps identify recruitment challenges early and set realistic timelines, reducing the risk of costly delays.

Optimizing Inclusion and Exclusion Criteria

By testing multiple eligibility scenarios on synthetic cohorts, teams can balance scientific rigor with patient availability. This leads to protocols that are both statistically sound and operationally feasible.

Better Site Selection and Geographic Planning

Synthetic data reflects population diversity across locations, enabling data-driven site selection. Sponsors can prioritize sites with higher enrollment potential and improved demographic representation.

Early Risk Identification and Mitigation

Trial simulations using synthetic data reveal risks such as underpowered designs or unreachable enrollment targets. Identifying these issues early helps prevent protocol amendments and trial failure.

Faster Go/No-Go Decisions with Greater Confidence

With faster feasibility assessments, organizations can evaluate multiple trial designs in parallel. This supports quicker, more confident go/no-go decisions and accelerates trial initiation.

Synthetic data doesn’t just make feasibility analysis faster; it makes it smarter, more reliable, and future-ready. By enabling simulation-driven planning, organizations can move from reactive trial execution to proactive trial design.

Key Use Cases of Synthetic Data in Clinical Trials

Synthetic data is already shaping how trials are planned and de-risked. Here’s how it’s being applied in real-world clinical scenarios.

Rare Disease Trial Planning

What if you could test feasibility before patients are even identified?

Synthetic data helps model realistic patient cohorts for rare diseases, enabling better recruitment forecasts and smarter protocol decisions, without depending on limited real-world data.

Smarter Oncology Trial Design

Complex eligibility criteria can slow trials down.

By simulating diverse tumor profiles, treatment responses, and imaging biomarkers using synthetic imaging models, synthetic data helps refine oncology trial protocols early and reduce screen failures later.

Recruitment & Enrollment Forecasting

Will patients enroll as planned?

Synthetic populations make it possible to predict enrollment rates across sites and regions, helping teams set realistic timelines and choose the right trial locations.

Optimizing Inclusion & Exclusion Criteria

Are your criteria too strict or too broad?

Synthetic data lets teams test how small eligibility changes impact patient pool size, diversity, and trial duration before the study begins.

“What-If” Trial Scenarios

What happens if dropout rates increase or protocols change?

Synthetic data enables fast scenario testing, supporting adaptive trial designs and proactive risk management.

Privacy-Safe Collaboration

How do teams collaborate without compromising patient privacy?

Synthetic data enables secure data sharing across sponsors and CROs, accelerating feasibility analysis while staying compliant.

Benefits of Using Synthetic Data in Trial Planning

Below are the key advantages of using synthetic data to design smarter, more feasible clinical trials.

Faster and More Confident Trial Design

Synthetic data allows teams to simulate trial scenarios early, helping sponsors and researchers test assumptions before committing real resources. This leads to better-informed protocol decisions and fewer surprises once the trial begins.

Improved Feasibility Assessment

By modeling realistic patient populations, synthetic data helps assess whether a trial is actually feasible, across eligibility criteria, geography, and timelines, reducing the risk of under-enrollment or delayed recruitment.

Reduced Costs and Delays

Early simulations uncover potential bottlenecks in recruitment, site selection, and study duration. Identifying these risks upfront minimizes expensive protocol amendments and shortens overall development timelines.

Enhanced Patient Recruitment Strategies

Synthetic datasets can reveal how small changes in inclusion and exclusion criteria impact patient availability, enabling teams to design more inclusive and patient-centric trials without compromising scientific rigor.

Stronger Data Privacy and Compliance

Because synthetic data does not represent real patients, it significantly reduces privacy risks. This makes it easier to explore scenarios, collaborate across teams, and stay aligned with data protection regulations.

Improved Cross-Team Collaboration

With privacy-safe datasets, sponsors, CROs, statisticians, and data scientists can collaborate more openly during trial planning without waiting for restricted access to real patient data.

Together, these benefits position synthetic data not just as a planning tool, but as a strategic advantage in modern clinical research.

Best Practices for Using Synthetic Data Effectively

Synthetic data can dramatically improve clinical trial simulation and feasibility studies, but only when it’s used thoughtfully. Here are the best practices that separate meaningful impact from experimental hype.

Start with Clear Clinical and Research Objectives

Define the exact purpose of using synthetic data, whether it’s enrollment forecasting, protocol optimization, or endpoint simulation. Clear objectives ensure the generated data aligns with real clinical and operational needs.

Base Synthetic Data on High-Quality Source Data

Synthetic data inherits patterns from its source datasets. Using well-curated, representative real-world data helps maintain clinical realism and prevents bias from being amplified in simulations.

Validate Synthetic Data Against Real-World Benchmarks

Always compare synthetic datasets with real-world data across demographics, disease progression, and outcomes. This validation ensures statistical fidelity and clinical credibility.

Involve Clinicians, Statisticians, and Data Scientists Early

Cross-functional collaboration ensures synthetic data is both technically sound and medically meaningful. Early clinical input helps avoid models that look correct on paper but fail in real-world scenarios.

Design for Privacy, Compliance, and Auditability

Ensure synthetic datasets eliminate re-identification risks while maintaining transparency in generation methods. Strong governance supports regulatory confidence and ethical clinical research.

Document Assumptions and Limitations Clearly

Every synthetic dataset is built on assumptions that influence outcomes. Clear documentation ensures stakeholders interpret simulation results correctly and make informed decisions.

By following these best practices, organizations can reduce risk, improve feasibility accuracy, and design trials that are faster, smarter, and more patient centric.

The Future of Clinical Trial Design with Synthetic Data

AI and Machine Learning-Driven Synthetic Data

AI and machine learning are making it possible to create highly realistic synthetic patient data. This allows researchers to simulate trials accurately, testing outcomes and protocols before involving real patients.

Adaptive and Personalized Trials

Synthetic data enables testing multiple trial scenarios virtually. This supports adaptive trials that adjust as new data comes in and helps design treatments for specific patient groups.

Integration with Real-World Evidence

Combining synthetic data with real patient data improves trial predictions. It helps researchers anticipate challenges, optimize enrollment, and better understand treatment effects across populations.

Regulatory Acceptance

Regulators like the FDA are exploring how synthetic data can support clinical research. Synthetic data is expected to play a growing role in navigating FDA approval, particularly during early trial design, feasibility assessments, and pre-IND interactions.

Cost and Time Efficiency

Synthetic data reduces the time and cost of trial planning and recruitment. Researchers can explore multiple trial designs virtually, lowering the risk of expensive failures.

Global Collaboration

Synthetic data can be shared safely across borders, encouraging collaboration. This allows multi-center virtual trials and broader research, including studies for rare diseases.

Synthetic data is shaping for a faster, safer, and smarter future for clinical trials. It bridges virtual simulations with real-world patient care, driving better decisions in drug development.

Conclusion

Clinical trials are about making the right decisions early. Synthetic data is enabling a fundamental shift in how feasibility studies and trial simulations are approached, helping research teams move from uncertainty to informed confidence. What once required costly amendments and trial restarts can now be addressed upfront with data-driven foresight.

With expertise in advanced analytics and synthetic data solutions, Ailoitte helps life sciences organizations plan smarter, faster, and more confident clinical trials, without compromising privacy or compliance.

Proactive planning and intelligent simulation will define the future of clinical trials, and synthetic data is the advantage that makes it possible.

Discover how Ailoitte AI keeps you ahead of risk

Let's Talk

Sunil Kumar

As a Principle Solution Architect at Ailoitte, Sunil Kumar turns cybersecurity chaos into clarity. He cuts through the jargon to help people grasp why security matters and how to act on it, making the complex accessible and the overwhelming actionable. He thrives where tech meets business